Curis to Present at Upcoming Healthcare Conference in April

Core Insights - Curis, Inc. is focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor [2] - The company will participate in the Jones Healthcare and Technology Innovation Conference on April 9, 2025, featuring a fireside chat and company presentation [1] Company Overview - Emavusertib is currently being evaluated in multiple clinical studies, including the Phase 1/2 TakeAim Lymphoma study for relapsed/refractory primary central nervous system lymphoma (PCNSL) and the Phase 1/2 TakeAim Leukemia study for relapsed/refractory acute myeloid leukemia (AML) [2] - The drug has received Orphan Drug Designation from the U.S. FDA for PCNSL, AML, and myelodysplastic syndrome (MDS) [2] - Curis has an exclusive license to emavusertib through a collaboration with Aurigene and has licensed its rights to Erivedge® to Genentech for commercialization [2]